Agamree有哪几个版本?分别多少钱?

Agamree is a new glucocorticoid drug mainly used to treat Duchenne muscular dystrophy (DMD). This article will introduce in detail the version information, price and accessibility of the drug in the Chinese market, providing patients and their families with a comprehensive medication reference.

What versions of Agamree are there

Currently there is only one standard preparation version in the world, which is developed and produced by Santhera Pharmaceuticals in Switzerland.

Single preparation specification

The active ingredient of Agamree is vamorolone. The existing preparation is an oral suspension with a unified specification of 40mg/mL. This standardized design simplifies clinical medication plans.

Packaging specifications

The medicine is packaged in standard packaging, and each box contains one 120mL bottle of suspension. This packaging design facilitates patient use and dosage adjustment while ensuring drug stability.

Understanding drug version information can help patients use it correctly and avoid medication errors caused by version confusion.

How much do different versions of Agamree cost?

As an innovative drug for the treatment of rare diseases, Agamree’s pricing is at a relatively high level, and the current global price is relatively uniform.

Official pricing

The price of Agamree announced by Swiss company Santhera is US$9,764 per box (120mL). This price reflects the research and development costs and market positioning of rare disease drugs.

Regional price differences

Some European countries have obtained 5-10% price discounts through medical insurance negotiations. The US market price is basically the same as that in Europe, but different pharmacy service fees may be attached.

Patient Assistance Program

Pharmaceutical companies provide cost reduction programs for eligible patients, and some patients can apply for subsidies of 30%-50% of drug prices.

Knowing drug price information can help patient families make treatment budgets and explore possible cost support options.

The listing and medical insurance status of Agamree in China

The accessibility of this drug in the Chinese market is currently greatly restricted, and patient access channels are limited.

Approval status

As of April 24, 2025, Agamree has not yet received marketing approval from the China National Medical Products Administration, and domestic patients are temporarily unable to purchase it through formal channels.

Medical insurance coverage

Since it has not been approved for marketing, the drug is naturally not included in any medical insurance reimbursement list, and patients need to pay for it in full.

Special access channels

Patients with urgent needs can apply for use through special policy areas such as Hainan Boao Lecheng International Medical Tourism Pilot Zone, or participate in international multi-center clinical trials.

Understanding the domestic marketing situation can help patients plan treatment plans rationally and find feasible alternatives.